Lech-Maranda Ewa, Bienvenu Jacques, Michallet Anne-Sophie, Houot Roch, Robak Tadeusz, Coiffier Bertrand, Salles Gilles
Equipe d'Accueil Pathologie des Cellules Lymphoïdes, Université Claude Bernard, Lyon, France.
Eur Cytokine Netw. 2006 Mar;17(1):60-6.
The aim of the study was to confirm whether plasma levels of interleukin-10 (IL-10) correlate with the prognosis in diffuse, large B-cell lymphoma (DLBCL) patients. Plasma IL-10 levels were determined at the time of diagnosis in a group of 157 consecutively treated, DLBCL patients. Of those, 122 patients (78%) had IL-10 plasma levels below the detection limit (< 5 pg/mL) and 35 (22%) above this value. The median value for patients with detectable IL-10 levels was 35 pg/mL (range, 5 to 2480 pg/mL). Detectable plasma IL-10 levels were significantly associated with age > 60 years, ECOG performance status > or = 2, Ann Arbor advanced disease stage, bulky tumor mass, elevated serum levels of LDH and beta2-microglobulin, presence of anemia and low serum albumin levels as well as the presence of B symptoms. The patients with detectable IL-10 levels had lower probability of CR achievement (OR = 0.23, 95% CI 0.1-0.5, p = 0.0003). In addition, detectable IL-10 levels were significantly associated with shorter PFS (OR = 2.5, 95% CI 1.5-4.4, p = 0.001) and OS (OR = 3.0, 95% CI 1.7-5.2, p = 0.0001). In conclusion, we confirmed in this large group of DLBCL patients that elevated plasma IL-10 levels correlated with adverse disease features and poor prognosis. The plasma concentration of IL-10 may be a useful marker for evaluation of disease activity.
该研究的目的是确认弥漫性大B细胞淋巴瘤（DLBCL）患者的血浆白细胞介素-10（IL-10）水平是否与预后相关。在一组157例接受连续治疗的DLBCL患者诊断时测定血浆IL-10水平。其中，122例患者（78%）的血浆IL-10水平低于检测限（<5 pg/mL），35例（22%）高于此值。IL-10水平可检测的患者的中位数为35 pg/mL（范围为5至2480 pg/mL）。可检测到的血浆IL-10水平与年龄>60岁、东部肿瘤协作组（ECOG）体能状态>或=2、Ann Arbor分期晚期、肿瘤体积大、血清乳酸脱氢酶（LDH）和β2-微球蛋白水平升高、贫血的存在、血清白蛋白水平低以及B症状的存在显著相关。IL-10水平可检测的患者达到完全缓解（CR）的概率较低（比值比[OR]=0.23，95%置信区间[CI]为0.1-0.5，p=0.0003）。此外，可检测到的IL-10水平与较短的无进展生存期（PFS）（OR=2.5，95%CI为1.5-4.4，p=0.001）和总生存期（OS）（OR=3.0，95%CI为1.7-5.2，p=0.0001）显著相关。总之，在这一大组DLBCL患者中我们证实，血浆IL-10水平升高与不良疾病特征和预后不良相关。IL-10的血浆浓度可能是评估疾病活动的有用标志物。
